Objective:

To enhance clinical and pathological understanding of primary large cell neuroendocrine carcinoma (LCNEC) of the breast, a rare subtype with diagnostic challenges.

Approach:

Key Findings:

• Primary LCNEC of the breast is extremely rare, with fewer than 10 documented cases.
• Accurate diagnosis is critical to distinguish LCNEC from other breast cancer subtypes, particularly TNBC.
• Immunohistochemistry is essential for diagnosis, revealing a unique triple-negative immunophenotype.

Interpretation:

Limitations:

• Short-term follow-up of 9 months limits the assessment of long-term efficacy and prognosis.
• The rarity of LCNEC results in limited comprehensive understanding and treatment guidelines.

Conclusion:

This case emphasizes the diagnostic challenges in identifying primary LCNEC of the breast.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.